EUVIMEDEUVIMED entdecken
Systematische Übersicht

Durio species and metabolic syndrome: A systematic review of bioactivity and phytochemistry

Islan Nor, Afrillia N. Garmana, Mohamad Rafi, Youngmin Kang, Muhamad Insanu

Journal of Pharmacy & Pharmacognosy Research · 01.07.2026 · 14 (4) · 2775

DOI: 10.56499/jppres_14.4.2775 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Pharmacy & Pharmacognosy Research, online erschienen am 01.07.2026. Verfasst von Islan Nor und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Metabolic syndrome is characterized by interrelated metabolic abnormalities, including hyperglycemia, dyslipidemia, hypertension, and central obesity, which collectively increase the risk of cardiovascular disease and type 2 diabetes mellitus. Plant-derived metabolites have been investigated as potential sources of pharmacological leads, and species of the genus Durio have been used as foods and in traditional medicine.

Aims

To systematically summarize evidence on Durio species, plant parts, extracts, and isolated compounds relevant to metabolic syndrome-related endpoints.

Methods

PubMed and Scopus were searched on May 28, 2024, for English-language articles published from 2004 to 2024. Records were screened in Covidence according to predefined eligibility criteria and the PRISMA 2020 framework. Data on plant species, plant part, extraction method, study design, assay or test method, and reported antidiabetic, antidyslipidemic, antioxidant, and phytochemical findings were extracted.

Results

Forty-five articles were included from 562 records. Direct antidiabetic and antidyslipidemic evidence was mainly reported for D. zibethinus. Antioxidant activity was also reported for D. zibethinus, D. kutejensis, D. kinabaluensis, and D. oxleyanus. Ninety isolated compounds were identified from Durio species; however, the metabolic relevance of many of these compounds was inferred from studies conducted outside Durio-derived matrices.

Conclusions

Current evidence suggests that Durio species, particularly D. zibethinus, may influence selected metabolic syndrome-related endpoints in preclinical and in vitro models. The evidence remains limited by heterogeneous assays, the absence of formal risk-of-bias assessment, and limited clinical data. Standardized phytochemical profiling, mechanistic studies, toxicity assessment, and controlled in vivo studies are needed.

Zitieren

APA

Nor, I., Garmana, A. N., Rafi, M., Kang, Y., & Insanu, M. (2026). Durio species and metabolic syndrome: A systematic review of bioactivity and phytochemistry. Journal of Pharmacy & Pharmacognosy Research, 14(4), 2775. https://doi.org/10.56499/jppres_14.4.2775

Vancouver

Nor I, Garmana AN, Rafi M, Kang Y, Insanu M. Durio species and metabolic syndrome: A systematic review of bioactivity and phytochemistry. Journal of Pharmacy & Pharmacognosy Research. 2026;14(4):2775. doi:10.56499/jppres_14.4.2775

BibTeX
@article{Nor2026,
  author = {Nor, Islan and Garmana, Afrillia N. and Rafi, Mohamad and Kang, Youngmin and Insanu, Muhamad},
  title = {Durio species and metabolic syndrome: A systematic review of bioactivity and phytochemistry},
  journal = {Journal of Pharmacy & Pharmacognosy Research},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {2775},
  doi = {10.56499/jppres_14.4.2775}
}
Kostenlos starten →